BioLargo (OTCQX: BLGO) CEO to host May 5 shareholder town hall

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

BioLargo, Inc. filed a current report announcing that CEO Dennis P. Calvert will participate in a shareholder town hall meeting on May 5, 2026 at 1:00 PM Pacific Time, hosted on the BioLargo Shareholder Community Discord channel.

The town hall will feature a brief company update followed by a Q&A session with shareholders. The meeting will be recorded and a transcript will be filed on Form 8‑K prior to the market open the next day. The company also includes standard forward-looking statement and Safe Harbor language referencing risks described in its most recent SEC filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Town hall date: May 5, 2026 Town hall time: 1:00 PM Pacific Time Transcript filing form: Form 8‑K

3 metrics

Town hall date May 5, 2026 Date of shareholder town hall meeting

Town hall time 1:00 PM Pacific Time Start time for the town hall meeting

Transcript filing form Form 8‑K Transcript will be filed on Form 8‑K prior to the market open the next day

Key Terms

Regulation FD, Form 8‑K, Safe Harbor Act, forward-looking statements, +1 more

5 terms

Regulation FD regulatory

"Item 7.01 Regulation FD Disclosure."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

Form 8‑K regulatory

"a transcript will be filed on Form 8‑K prior to the market open"

A Form 8-K is a required public filing companies use to report important, time-sensitive events—like leadership changes, major contracts, financial restatements, or other developments—that could affect a company’s value. Think of it as a breaking-news alert for investors: it provides quick, official details so shareholders and the market can reassess risk and price the stock based on the new information.

Safe Harbor Act regulatory

"For important information about forward looking statements, see the information under the heading “Safe Harbor Act”"

forward-looking statements regulatory

"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Private Securities Litigation Reform Act of 1995 regulatory

"forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995."

Understanding 8-K Material Events →

05/04/2026 - 07:30 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 4, 2026

BioLargo, Inc.

(Exact name of registrant as specified in its charter)

Delaware		000-19709		65-0159115
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

14921 Chestnut St., Westminster, California		92683
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 400-2863

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BLGO	OTCQX

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

BioLargo, Inc., published the press released attached as Exhibit 99.1, which is incorporated by this reference, on May 4, 2026.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the exhibits to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading “Safe Harbor Act” in the exhibits attached hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.	Description
99.1	Press release
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: May 4, 2026	BIOLARGO, INC.

	By:	/s/ Dennis P. Calvert
		Dennis P. Calvert
		President and Chief Executive Officer

EXHIBIT 99.1

BioLargo to Participate in a Town Hall Meeting Hosted by the BioLargo Shareholder Community on Discord on May 5, 2026

A meeting transcript will be published by 8-K prior to the market open the next day

WESTMINSTER, CALIFORNIA – May 4, 2026— BioLargo, Inc. (OTCQX: BLGO), a cleantech and life sciences innovator, today announced that BioLargo’s CEO Dennis P. Calvert will participate in a town hall meeting on May 5, 2026 at 1:00 PM Pacific Time, hosted on the BioLargo Shareholder Community Discord channel.

The format: brief company update followed by Q&A with shareholders. The meeting will be recorded and a transcript will be filed on Form 8‑K prior to the market open the next day.

Questions may be pre-submitted on the Discord channel (#townhall-questions-may-5-2026 (https://discord.com/channels/838045954589327373/1499782837342175454)

Interested parties are encouraged to join the BioLargo Shareholder Community Discord in advance by accessing the platform here: Join the BioLargo Town Hall Meeting Hosted at Discord (https://discord.gg/xEd9KqcU?event=1499864645417308190)

For more detail and to submit questions to the moderators, participants can visit the r/BioLargo announcement at the following link hosted on Reddit: Reddit Platform Link to Town Hall Meeting Details (https://www.reddit.com/r/BioLargo/comments/1t17jbc/official_biolargo_shareholder_town_hall_with_ceo/)

About BioLargo, Inc.

BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Email: Info@BioLargo.com

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Source: View Original Filing on SEC EDGAR

FAQ

What did BioLargo (BLGO) announce in this 8-K filing?

BioLargo announced that CEO Dennis P. Calvert will participate in a shareholder town hall meeting on May 5, 2026, hosted on the company’s Discord channel, with a brief corporate update followed by a Q&A session and a transcript to be filed on Form 8‑K.

When and where is the BioLargo (BLGO) shareholder town hall being held?

The shareholder town hall is scheduled for May 5, 2026 at 1:00 PM Pacific Time. It will be hosted on the BioLargo Shareholder Community Discord channel, allowing investors and interested parties to join online and interact directly with company leadership.

Will a transcript of the BioLargo (BLGO) town hall be available?

Yes. The company states the town hall will be recorded and a transcript will be filed on Form 8‑K prior to the market open the next day, allowing shareholders who cannot attend live to review management’s comments and Q&A exchanges.

How can investors participate in BioLargo’s May 5, 2026 town hall?

Investors can join via the BioLargo Shareholder Community Discord channel, with links provided in the announcement. Questions may be pre-submitted using the specified Discord channel, and additional details are available through an accompanying Reddit announcement post about the town hall.

What topics will be covered during the BioLargo (BLGO) town hall meeting?

The company describes the format as a brief business update followed by Q&A with shareholders. While specific topics are not itemized, investors can submit questions in advance, so the discussion will likely reflect current shareholder interests and management’s prepared update.

What kind of business does BioLargo (BLGO) operate according to this filing?

BioLargo is described as a cleantech and life sciences innovator and engineering services solution provider. Its core products address PFAS contamination, advanced water and wastewater treatment, odor and VOC control, air quality, energy-efficiency and safe on-site energy storage, and infection and infectious disease control.

Filing Exhibits & Attachments

5 documents

Press Releases

EX-99.1 EXHIBIT 99.1 - PRESS RELEASE 7.0 KB